Results 31 to 40 of about 539,919 (309)

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]

, 2018
In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A., Marchetti, P., Nuti, M., Rughetti, A., Zizzari, I. G.   +4 more
core   +1 more source

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

Journal for ImmunoTherapy of Cancer, 2017
Background Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogeneity has not been extensively ...
Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez, Constantin N. Baxevanis   +11 more
doaj   +1 more source

The inhibitory SAPS3–AMPK interaction detected in HEK293 cells is not detectable in muscle or liver from humans or mice

FEBS Letters, EarlyView.
This study challenges the idea that Sit4‐associated protein subunit 3 (SAPS3) inhibits the energy‐sensing enzyme AMP‐activated protein kinase (AMPK) in muscle and liver tissue. Although SAPS3 interacts with AMPK in cultured cells, we found no such interaction in human or mouse tissues subjected to fasting, exercise, or a high‐fat diet.
Jesper B. Birk, Maria A. Møller, Jørgen F.P. Wojtaszewski, Rasmus Kjøbsted   +3 more
wiley   +1 more source

Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients

Nature Communications, 2023
Efficacy of cancer vaccines remains low and mechanistic understanding of antigen presenting cell function in cancer may improve vaccine design and outcomes.
Juraj Adamik, Paul V. Munson, Deena M. Maurer, Felix J. Hartmann, Sean C. Bendall, Rafael J. Argüello, Lisa H. Butterfield   +6 more
doaj   +1 more source

The role of histone modifications in transcription regulation upon DNA damage

FEBS Letters, EarlyView.
This review discusses the critical role of histone modifications in regulating gene expression during the DNA damage response (DDR). By modulating chromatin structure and recruiting repair factors, these post‐translational modifications fine‐tune transcriptional programmes to maintain genomic stability.
Angelina Job Kolady, Siyao Wang
wiley   +1 more source

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

Cancer Medicine, 2020
Background Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor therapy.
Mark Yarchoan, Chiung‐Yu Huang, Qingfeng Zhu, Anna K. Ferguson, Jennifer N. Durham, Robert A. Anders, Elizabeth D. Thompson, Noah S. Rozich, Dwayne L. Thomas II, Julie M. Nauroth, Christina Rodriguez, Arsen Osipov, Ana De Jesus‐Acosta, Dung T. Le, Adrian G. Murphy, Daniel Laheru, Ross C. Donehower, Elizabeth M. Jaffee, Lei Zheng, Nilofer S. Azad   +19 more
doaj   +1 more source

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source

Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer

Journal for ImmunoTherapy of Cancer, 2019
Background Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy.
A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor, Kunle Odunsi   +11 more
doaj   +1 more source

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells [PDF]

, 2016
Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation
Bown, James, Deeni, Yusuf Y., Goltsov, Alexey, Harrison, David J., Khalil, Hilal S., Langdon, Simon P., Soininen, Tero   +6 more
core   +3 more sources

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source